Quantcast

Evaluation of the performance of 5 commercialized enzyme immunoassays for the detection of Taenia solium antibodies and for the diagnosis of neurocysticercosis.

Research paper by Jean-François JF Carod, Mickaël M Randrianarison, Julien J Razafimahefa, Rondro Mamitiana RM Ramahefarisoa, Mahenintsoa M Rakotondrazaka, Monique M Debruyne, Mélanie M Dautigny, Pierrette P Cazal, Marcellin Lalaoarisoa ML Andriantseheno, Emile Ramarokoto ER Charles

Indexed on: 17 Nov '11Published on: 17 Nov '11Published in: Diagnostic Microbiology and Infectious Disease



Abstract

This study aimed to evaluate 5 enzyme immunoassays for detecting human antibodies against Taenia solium in human serum and for the diagnosis of neurocysticercosis (NCC): DRG™, RIDASCREEN™, NOVATECH™, CYPRESS™, and IVD™. A collection of 114 reference serum samples were used. All sera were tested both by ELISA and by an immunoblot method (enzyme-linked immunoelectrotransfer blot [EITB]). When compared with EITB, the Ridascreen™ test had the best positive concordance rate (85.1-91.2%) and the NovaLisa test™ showed the optimal negative concordance rate (93.7-95.6%). All tests had a sensitivity under 72% and a specificity above 60%. The best sensitivity was obtained using Ridascreen™ test (71.4%). An optimal specificity was achieved by the NovaLisa test™. T. solium-positive sera all cross-reacted with E. granulosus positive samples. In the commercial assays evaluated here, the most appropriate ELISA test for screening may be the Ridascreen™ assay. Antibody detection seems to be not appropriate for NCC diagnosis because of its overall lack of sensitivity.